Evidence-based insights into peptide protocols, safety research, and optimization strategies. Built on clinical rigor, powered by community knowledge.
Get weekly insights on peptide protocols, safety updates, and optimization strategies delivered to your inbox.
No spam. Unsubscribe anytime. Clinical rigor, always.
35+
Articles
18
Categories
Deep dives into peptide science — evidence-graded, honestly reported
Peptides send the signal — but without the right micronutrient partners, the instruction falls flat. Here's the biochemistry behind why your protocol needs more than peptides.
Evidence-graded analysis of the micronutrient co-factors that determine whether peptide therapy delivers results — from Vitamin C and collagen synthesis to zinc and the IGF-1 axis, plus the contested evidence and research gaps the field still needs to close.
Comprehensive outcome research with safety data and practical protocol references
Detailed compound profiles with mechanisms, safety data, and dosing protocols
Evidence-based supplement stacks designed to support your peptide protocols
Evidence-graded testosterone profiles by ester and formulation, with safety data and peptide alternatives
Cardiac peptide therapy isn't science fiction — Tβ4 has completed Phase 2 in acute MI (NCT05984134), and SS-31 sits in advanced-phase trials for mitochondrial heart disease.
A plain-English look at the peptides being investigated for cardiovascular repair — Thymosin β4 for post-infarct tissue regeneration, elamipretide for mitochondrial membrane stability, and the adjacent vascular-bioregulator layer.
A D-retro-inverso peptide that selectively kills senescent cells by disrupting the FOXO4-p53 survival interaction, triggering mitochondrial apoptosis in aged 'zombie' cells while sparing healthy tissue.
FOXO4-DRI breaks the molecular shield that keeps senescent cells alive. By freeing p53 from FOXO4 sequestration, it triggers selective apoptosis in aged cells, restoring kidney function, testosterone levels, and tissue vitality in preclinical models.
A selective ghrelin mimetic that triggers your pituitary to release growth hormone without touching cortisol, prolactin, or appetite.
Ipamorelin is a synthetic pentapeptide and the first truly selective growth hormone secretagogue. It binds the GHS-R1a receptor to trigger pulsatile GH release without the hormonal side-channel activation that defined earlier peptides like GHRP-6.
A synthetic GHRH analog that tells your pituitary to release its own growth hormone, not inject someone else's.
CJC-1295 is a 29-amino acid GHRH analog engineered to resist enzymatic breakdown. It stimulates endogenous GH pulses rather than flooding the system with synthetic hormone, offering a fundamentally different risk-benefit profile to direct HGH therapy.
A naturally occurring tripeptide locked inside your collagen that modulates 4,192 human genes, acts as a safe copper chaperone, and signals systemic repair, with plasma levels dropping 60% between ages 20 and 60.
GHK-Cu (Glycyl-L-Histidyl-L-Lysine) is a naturally occurring tripeptide embedded in Type I collagen. Liberated during tissue injury, it acts as a master repair signal modulating 4,192 human genes (roughly one-third of the genome). It drives collagen synthesis, delivers copper safely to enzymes like Superoxide Dismutase via a unique square-planar pyramid configuration, and shows emerging potential in gut barrier repair (SIRT1/STAT3) and COPD reversal (127-gene signature). Plasma levels decline 60% by age 60. Clinical protocols use a biphasic 30-day cycle (1mg escalating to 2mg) with a mandatory 30-day rest. FDA Category 2 restricts legal compounding for systemic use. Contraindicated in active malignancies and Wilson's Disease.
A four-amino-acid peptide that activates telomerase, remodels chromatin, and restores melatonin synthesis from the pineal gland — addressing five hallmarks of aging simultaneously. The Russian clinical data spans 12–15 years. Independent Western replication barely exists.
Epitalon (AEDG) is a synthetic tetrapeptide modeled after the bovine pineal extract Epithalamin. It upregulates hTERT to activate telomerase, remodels heterochromatin to re-access silenced genes, restores endogenous melatonin production (160% increase in clinical trials), and demonstrated a 28% decrease in overall mortality over a 12-year human follow-up. A 2025 study revealed selective ALT pathway activation in cancer cells. The compound remains investigational — nearly all positive data originates from a single institutional network in St. Petersburg, and independent Western replication is virtually absent.
A 16-amino-acid mitochondrial messenger that mimics exercise at the cellular level — activating AMPK, reprogramming metabolism, and writing survival instructions directly into the nucleus. The science is striking. The stability problem is brutal.
MOTS-c is a mitochondrial-derived peptide (mitokine) that acts as an exercise mimetic through the Folate-AICAR-AMPK axis. It translocates to the nucleus under metabolic stress, enhances glucose uptake via GLUT4, promotes white-to-brown fat conversion, and reprograms immune cells toward anti-inflammatory phenotypes. A natural longevity variant (K14Q) exists in East Asian populations. Clinical translation is hampered by extreme instability (85–90% activity loss in 2–3 hours at room temperature) and a circulating half-life of only 1–2 hours.
The biochemical cofactors your body needs to support Selank therapy.
Evidence-based supplement companion for Selank — a tuftsin-derived heptapeptide that delivers benzodiazepine-level anxiety relief without sedation, dependence, or cognitive fog — while simultaneously boosting immune defence.
Two routes, one molecule: how undecanoate rewrote the oral testosterone playbook and what the TRAVERSE trial actually proved about heart safety.
Testosterone undecanoate is the only ester available as both a long-acting injectable (Aveed, Nebido) and a twice-daily oral (Jatenzo, Kyzatrex). Its lymphatic absorption bypasses the liver entirely, solving the hepatotoxicity problem that killed earlier oral steroids. The TRAVERSE trial confirmed cardiovascular non-inferiority, but flagged atrial fibrillation and kidney injury signals that demand ongoing monitoring.
The first synthetic testosterone ester (1936), with a 2-4.5 day half-life that demands daily or EOD dosing. What the clinical data says about the fertility paradox, rapid washout safety, microdosing, and why this 'relic' is the precision tool of modern endocrinology.
Evidence-graded profile of testosterone propionate: the fastest-acting injectable ester, its fertility paradox from murine data, the washout safety net for women and diagnostics, PIP solutions through microdosing, circadian alignment, age-stratified risk, and peptide alternatives.
The most prescribed testosterone ester outside the US, with a 4.5-7 day half-life that demands weekly dosing for stable levels. What the clinical data says about the hepcidin hijack, erythrocytosis, and why dosing frequency matters more than dose size.
Evidence-graded profile of testosterone enanthate: the hepcidin mechanism behind erythrocytosis, DHT and the scrotal paradox, dosing frequency pharmacokinetics, the TRAVERSE prostate saturation model, age-stratified risk, and peptide alternatives.
The most prescribed testosterone ester in the US, with an 8-day half-life that makes it the backbone of modern TRT. What the clinical data actually says about how to use it.
Evidence-graded profile of testosterone cypionate: pharmacokinetics, subcutaneous vs intramuscular data, the TRAVERSE trial's cardiovascular findings, age-stratified risk, and where peptides fit alongside.